Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

Droplet digital PCR measurements of circulating tumor (ct)DNA to assess minimal residual disease before the initiation of ...

Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify ...

Researchers used digital polymerase chain reaction assays to measure BRAF V600E or BRAF V600K circulating tumor DNA in ...

Biomarkers, precision medicine, early detection to revolutionize CRC care in India: Dr. Sumant Gupta: Shardul Nautiyal, ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

Survey respondents identified three biomarkers that most often had to be requested if not included in the original pathology workup — PD-L1 (48%), TMB (32%) and BRAF p.V600E (32%).

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025.

Metanephric adenoma (MA) is a rare benign renal tumor, with an incidence of 0.2%–1%. Approximately 90% of MA cases present with the BRAF V600E mutation. This study ...

Doctors can treat this using targeted therapy drugs called BRAF inhibitors. These medicines attack the BRAF protein and shrink or slow the growth of the cancer cells. If checkpoint inhibitors are ...

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union ...